Physician profile
Edward Wayne Fox
NPI 1578988291
$1,915.72
in general payments reported to CMS, 2019-2025
11 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $256 · 2023: $550 · 2024: $511 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.57 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $334.02 | 2021-2024 | Ingrezza |
| Alkermes, INC. | $206.86 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Inari Medical, INC. | $188.74 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Axsome Therapeutics, INC. | $143.86 | 2025 | Auvelity |
| Abbvie INC. | $140.40 | 2024 | |
| Silk Road Medical, INC. | $136.77 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Vanda Pharmaceuticals INC. | $124.99 | 2024 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $122.82 | 2022-2023 | Austedo Xr |
| Eisai INC. | $117.03 | 2021 | |
| Indivior INC. | $23.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.